SEARCH

SEARCH BY CITATION

References

  • 1
    Charles J, Valenti L, Britt H. BPH – Management in general practice. Aust Fam Physician 2011; 40: 757
  • 2
    Parsons JK. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr Bladder Dysfunct Rep 2010; 5: 212218
  • 3
    Thangasamy IA, Chalasani V, Bachmann A, Woo HH. Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: A systematic review with meta-analysis from 2002 to 2012. Eur Urol 2012; 62: 315323
  • 4
    Stafinski T, Menon D, Harris K, Md GG, Jhangri G. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia. Can Urol Assoc J 2008; 2: 124134
  • 5
    Ahmed HU, Thwaini A, Shergill IS et al. Greenlight prostatectomy: a challenge to the gold standard? A review of KTP photoselective vaporization of the prostate. Surg Laparosc Endosc Percutan Tech 2007; 17: 156163
  • 6
    Ruszat R, Wyler S, Forster T et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 2007; 51: 10311038
  • 7
    Al-Ansari A, Younes N, Sampige VP et al. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up. Eur Urol 2010; 58: 349355
  • 8
    Horasanli K, Silay MS, Altay B, Tanriverdi O, Sarica K, Miroglu C. Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial. Urology 2008; 71: 247251
  • 9
    Capitan C, Blazquez C, Martin MD, Hernandez V, de la Pena E, Llorente C. GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: a randomized clinical trial with 2-year follow-up. Eur Urol 2011; 60: 734739
  • 10
    Medical Advisory Secretariat. Energy delivery systems for treatment of benign prostatic hyperplasia. Toronto, Ontario: Ontario Ministry of Health and Long Term Care, 2006
  • 11
    Ruszat R, Wyler S, Seifert HH et al. Photoselective vaporization of the prostate: subgroup analysis of men with refractory urinary retention. Eur Urol 2006; 50: 10401049
  • 12
    Bouchier-Hayes DM, Van Appledorn S, Bugeja P, Crowe H, Challacombe B, Costello AJ. A randomized trial of photoselective vaporization of the prostate using the 80-W potassium-titanyl-phosphate laser vs transurethral prostatectomy, with a 1-year follow-up. BJU Int 2010; 105: 964969
  • 13
    Stovsky MD, Griffiths RI, Duff SB. A clinical outcomes and cost analysis comparing photoselective vaporization of the prostate to alternative minimally invasive therapies and transurethral prostate resection for the treatment of benign prostatic hyperplasia. J Urol 2006; 176: 15001506
  • 14
    Goh AC, Gonzalez RR. Photoselective laser vaporization prostatectomy versus transurethral prostate resection: a cost analysis. J Urol 2010; 183: 14691473
  • 15
    Manager Technical Activity Based Funding Model Team. Queensland Clinical Costing Standards v1.0. Brisbane: Queensland Health, 2011 Oct 13
  • 16
    Chung DE, Wysock JS, Lee RK et al. Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia. J Urol 2011; 186: 977981
  • 17
    Vale J. Benign prostatic hyperplasia and erectile dysfunction – is there a link? Curr Med Res Opin 2000; 16 (Suppl. 1): s6367